Spanish pharmaceutical company Almirall has entered into an agreement to acquire Allergan’s US medical dermatology unit portfolio, consisting of five brands for acne and dermatoses treatment.
The brands include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (fludroxycortide), as well as Seysara (sarecycline), a new tetracycline-derived antibiotic with antiinflammatory qualities for treating moderate to severe acne.
According to the companies, the FDA approval of Seysara is anticipated towards the end of this year. All products will be distributed through Almirall’s US team.
Peter Guenter, CEO at Almirall, noted, “This is a transformational deal for Almirall. It will reinforce and consolidate our position in the world’s largest dermatology market and is a well balanced portfolio of mature and growth brands with a major launch opportunity of an innovative new chemical entity.”
The deal, which is conditional to clearance by the relevant authorities, is expected to close in the final quarter of this year.